PSYENCE BIOMEDICAL LTD
PBMNASDAQTrading Snapshot
- Day Range
- $5.42 – $5.51
- 52-Week Range
- $1.92 – $175.78
- Volume
- $3.01B
- Avg Volume
- $3.83B
- Shares Outstanding
- 19,018
- Next Earnings
- Nov 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $51,786
- Last Q Revenue
- $12,112
- P/E Ratio
- -0.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-12.56
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +435.4%
Why Investors Own PBM
- ✓High-growth profile — revenue up +30.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 33% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PSYENCE BIOMEDICAL LTD
PBM
StockOtter · stockotter.spaceAbout PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
Binding term sheet with PsyLabs provides Psyence BioMed's Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs' pharmaceutical-grade ibogaine, subject to a definitive agreement Bind
Psyence BioMed Announces Strategic Ibogaine Investment
Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential ibogaine clinical tria
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
HIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine development Positioned to hold U.S. rights to PsyLabs' pharmaceutical-grade ibogaine, subject to completion of definitive licens
Modular Medical Secures National PBM Contract For Pivot Insulin Pump
Commercial-stage medical device manufacturer Modular Medical Inc. (NASDAQ:MODD) recently signed a significant contract with a national U.S. pharmacy benefit manager (PBM).
Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development
Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built Company says growing federal commitment to ibogaine aligns direc